InMed Average Payables from 2010 to 2025

INM Stock  USD 2.65  0.20  7.02%   
InMed Pharmaceuticals Average Payables yearly trend continues to be very stable with very little volatility. Average Payables is likely to drop to about 156.7 K. Average Payables is the average amount owed to suppliers and creditors over a specific period, reflecting InMed Pharmaceuticals' payment cycle and credit terms with suppliers. View All Fundamentals
 
Average Payables  
First Reported
2010-12-31
Previous Quarter
165 K
Current Value
156.7 K
Quarterly Volatility
432.7 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check InMed Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among InMed Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 284.9 K, Interest Expense of 153.3 K or Selling General Administrative of 6.3 B, as well as many indicators such as Price To Sales Ratio of 9.11, Dividend Yield of 0.0 or PTB Ratio of 4.55. InMed financial statements analysis is a perfect complement when working with InMed Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of InMed Pharmaceuticals Correlation against competitors.
To learn how to invest in InMed Stock, please use our How to Invest in InMed Pharmaceuticals guide.

Latest InMed Pharmaceuticals' Average Payables Growth Pattern

Below is the plot of the Average Payables of InMed Pharmaceuticals over the last few years. It is the average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers. InMed Pharmaceuticals' Average Payables historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in InMed Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Average Payables10 Years Trend
Slightly volatile
   Average Payables   
       Timeline  

InMed Average Payables Regression Statistics

Arithmetic Mean520,076
Geometric Mean281,953
Coefficient Of Variation83.20
Mean Deviation391,510
Median585,184
Standard Deviation432,716
Sample Variance187.2B
Range1.1M
R-Value0.32
Mean Square Error180.6B
R-Squared0.1
Significance0.23
Slope28,703
Total Sum of Squares2.8T

InMed Average Payables History

2025156.7 K
2024165 K
2023585.2 K
2022855.1 K
2019970.6 K
20171.1 M

About InMed Pharmaceuticals Financial Statements

InMed Pharmaceuticals investors utilize fundamental indicators, such as Average Payables, to predict how InMed Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Average Payables165 K156.7 K

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether InMed Pharmaceuticals is a strong investment it is important to analyze InMed Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact InMed Pharmaceuticals' future performance. For an informed investment choice regarding InMed Stock, refer to the following important reports:
Check out the analysis of InMed Pharmaceuticals Correlation against competitors.
To learn how to invest in InMed Stock, please use our How to Invest in InMed Pharmaceuticals guide.
You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of InMed Pharmaceuticals. If investors know InMed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about InMed Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(11.26)
Revenue Per Share
8.473
Quarterly Revenue Growth
(0.10)
Return On Assets
(0.41)
Return On Equity
(0.83)
The market value of InMed Pharmaceuticals is measured differently than its book value, which is the value of InMed that is recorded on the company's balance sheet. Investors also form their own opinion of InMed Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is InMed Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because InMed Pharmaceuticals' market value can be influenced by many factors that don't directly affect InMed Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between InMed Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if InMed Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, InMed Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.